Gould Capital’s Quest Diagnostics DGX Stock Holding History

Gould Capital’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$37K	Buy	189 +18	+11%	+$3.5K	0.02%	95
2025 Q4	$29.7K	Hold	171	–	–	0.02%	101
2025 Q3	$32.6K	Hold	171	–	–	0.02%	100
2025 Q2	$30.7K	Hold	171	–	–	0.02%	97
2025 Q1	$28.9K	Sell	171 -7	-4%	-$1.15K	0.02%	96
2024 Q4	$26.9K	Hold	178	–	–	0.02%	107
2024 Q3	$27.6K	Hold	178	–	–	0.02%	110
2024 Q2	$24.4K	Hold	178	–	–	0.02%	116
2024 Q1	$23.7K	Buy	178 +35	+24%	+$4.54K	0.02%	114
2023 Q4	$19.7K	Buy	143 +9	+7%	+$1.18K	0.01%	130
2023 Q3	$16.2K	Hold	134	–	–	0.01%	127
2023 Q2	$18.8K	Hold	134	–	–	0.01%	124
2023 Q1	$19K	Sell	134 -1	-0.7%	-$143	0.01%	123
2022 Q4	$21.1K	Hold	135	–	–	0.02%	112
2022 Q3	$17K	Hold	135	–	–	0.01%	116
2022 Q2	$18K	Hold	135	–	–	0.01%	114
2022 Q1	$18K	Buy	135 +3	+2%	+$418	0.01%	124
2021 Q4	$23K	Buy	+132	New	+$20.1K	0.02%	118

Other funds holding DGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Gould Capital's DGX Position: Q1 2026 in Review

Gould Capital increased its Quest Diagnostics (DGX) stake by 11% in Q1 2026, buying an estimated $3.5K and bringing the position to 189 shares worth $37K. The position accounts for 0.02% of the portfolio, ranked #95.

Gould Capital first reported a position in DGX in Q4 2021 and has held it in 18 quarters since. 1,063 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

Gould Capital held 189 shares of Quest Diagnostics worth $37K as of Q1 2026.
Gould Capital bought 18 Quest Diagnostics shares in Q1 2026, an estimated $3.5K.
Quest Diagnostics made up 0.02% of Gould Capital's portfolio in Q1 2026, its #95 holding.
Gould Capital first reported a position in Quest Diagnostics in Q4 2021 and has held it in 18 quarters since.
1,063 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Gould Capital's 13F filing for Q1 2026, filed 18 May 2026.